{"id":969,"date":"2021-09-13T15:05:08","date_gmt":"2021-09-13T15:05:08","guid":{"rendered":"http:\/\/gpswp.com\/cooperfinancial-new\/?page_id=969"},"modified":"2021-09-22T17:41:58","modified_gmt":"2021-09-22T17:41:58","slug":"market-reflection","status":"publish","type":"page","link":"https:\/\/gpswp.com\/cooperfinancial\/services\/market-reflection\/","title":{"rendered":"Market Reflection"},"content":{"rendered":"\n

November – 2020<\/h1>\n\n\n\n

“Stock Market Checklist<\/em>“<\/h3>\n\n\n\n
\"market-reflection\"\/<\/figure>\n\n\n\n

The markets in 2020 have been defined by COVID-19, or the coronavirus. Centered around the markets and their performance has been the restrictions to the economy in order to contain the virus, and the timeline of reopening and the reengagement of activities that were part of our lives pre-COVID. As restrictions around social distancing carry significant impact to our daily lives, a concentrated focus has been on our ability to treat or vaccinate COVID-19 and the timeline of implementation. Yesterday, the world received significant news via the Pfizer\/BioNTech vaccine announcement, and we felt it was prudent to update on the status of COVID vaccinations as well as our adjustments considering recent events.<\/p>\n\n\n\n

As of November 3, there were 47 COVID-19 vaccine candidates in clinical evaluation \u2013 nine in Phase III clinical trials \u2013 and 155 in preclinical evaluation1 according to the WHO website. The picture below describes the various phases of a clinical trial2<\/sup>.<\/p>\n\n\n\n

\"market-reflection\"\/<\/figure>\n\n\n\n

Vaccines, from preclinical trial to adoption, typically require years of research and patient testing before patient use. On Monday November 9, however, Pfizer and BioNTech delivered initial Phase III data that indicated their COVID-19 vaccine was over 90 percent effective. This was the first vaccine to have such an indication and caused the market to have a very favorable reaction.<\/p>\n\n\n\n

As an example of the strength of initial efficacy, according the interim data released by the CDC, the flu vaccine for the 2019-2020 season has been 45% effective against influenza A and B viruses (50% effective against influenza B and 37% effective against influenza A)3. With the COVID-19 vaccine at 90% efficacy on the initial update from the Phase III trial period, this could mean a quicker transition to a \u201cherd immunity\u201d as more people may be willing to take the vaccine based on the high level of effectiveness.<\/p>\n\n\n\n

Pfizer and BioNTech are expected to release further data in late November with potential for Emergency Use Authorization and production beginning in December. Currently, the firms intend to produce up to 50 million doses by the end of 2020 and up to 1.3 billion doses by the end of 2021. However, challenges remain in getting the vaccine to patients include:<\/p>\n\n\n\n